Short answer
Mirum Pharmaceuticals, Inc. (MIRM) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $133M (up 47.2% year over year) with net income of $3M.
Q3 2025 key financials · XBRL
- Revenue
- $133M
- +47.2% YoY · +4.1% QoQ
- Net income
- $3M
- +120.4% YoY · +149.6% QoQ
- Operating margin
- 2.0%
- EPS (diluted)
- $0.07
- +123.3% YoY · +158.3% QoQ
Source: XBRL data from the Mirum Pharmaceuticals, Inc. (MIRM) Q3 2025 10-Q on SEC EDGAR. USD.
Mirum Pharmaceuticals, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: EU HTA Regulation 2021/2282 effective Jan 12, 2025 may delay/refine pricing and reimbursement assessments impacting revenue in EU markets
- Updated reimbursement risk: Elimination of Medicaid rebate cap effective Jan 1, 2024 increases rebate costs and compliance complexity under Medicaid Drug Rebate Program
- Regulatory risk: Potential termination from Medicaid rebate program triggers loss of federal Medicaid/Medicare payments for covered outpatient drugs
- Operational risk: Challenges in growing and sustaining sales force and third-party marketing negatively affect near-term commercialization of Livmarli, Cholbam, Ctexli
- Financial risk: Time lag of several months in rebate invoicing under government programs complicates accurate rebate accrual and financial forecasting
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Mirum Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.